Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Tranexamic acid ...

Prophylactic tranexamic acid (TXA) during cesarean delivery did not lead to a lower risk of maternal death or blood transfusion, a randomized trial found. Among 11,000 women in 31 U.S. hospitals ...

Topical and intravenous tranexamic acid (TXA) were found to significantly reduce blood loss compared with placebo in patients who have undergone bone surgery, suggesting that both administration ...

The antifibrinolytic tranexamic acid (TXA) reduced serious bleeding without a significant effect on major vascular outcomes in patients undergoing noncardiac surgery at risk for these complications in ...

Please provide your email address to receive an email when new articles are posted on . This study reports results from a prospective, randomized, double-blind trial. Use of IV tranexamic acid did not ...

Tranexamic acid (TXA) use is set to widen in England and Wales under new draft guidance from the National Institute for Health and Care Excellence (NICE). NICE recommends offering TXA before any ...

Within 4 weeks of starting treatment, patients experienced improvements in their condition, indicating an anti-inflammatory effect of the treatment. Study findings are supporting the use of 10% ...